Ozempic Rash and Itching: Skin Reactions on GLP-1s, Explained

“Ozempic rash” is the search-box name for the skin reactions people notice after starting a GLP-1 medication — semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). In practice it covers three very different things, and the whole point of this article is to keep them separate. First, the common one: a small patch of redness, itching, or a little welt or firm bump right where you inject — an injection-site reaction, usually mild and short-lived. Second, the less common one: a more widespread rash or generalized itching over the body. Third, and rare but genuinely serious: a hypersensitivity reaction — hives spreading fast, swelling of the lips, tongue, or throat (angioedema), trouble breathing (anaphylaxis), or a delayed drug-rash syndrome with fever. The first is normal and manageable. The third is a stop-the-drug-and-get-care emergency. This guide covers what each looks like, how long it lasts, what helps, what is and is not normal, and the specific red flags that mean call for help now — for both semaglutide and tirzepatide, including a note on compounded products.

The three kinds of skin reaction on a GLP-1

Lumping every skin change under “Ozempic rash” is what causes the confusion — and either needless panic or, worse, ignoring a real warning sign. The clinical literature on GLP-1 receptor agonist skin effects sorts them along a clear gradient from common-and-mild to rare-and-serious (Ho 2026^[4]; Vyas 2026^[5]). Here is the map.

Injection-site reactions — the common, usually mild one

By far the most frequent skin complaint on a GLP-1 is a local injection-site reaction: redness, itching, mild tenderness, or a small raised welt or firm bump exactly where the needle went in. It typically shows up within hours to a day or two of dosing and fades over a few days. In the pivotal trials these reactions were generally mild and rarely a reason to stop — in SUSTAIN-6, injection-site reactions with subcutaneous semaglutide were uncommon and predominantly mild (Marso 2016^[3]), and the large obesity trials of semaglutide (Wilding 2021^[2]) and tirzepatide (Jastreboff 2022^[1]) reported injection-site reactions as a recognized but generally minor adverse event rather than a frequent serious one.

A specific, well-documented variant is a persistent firm nodule under the skin at the injection site. Most are described with the longer-acting exenatide formulations, where the microsphere delivery system can provoke a localized inflammatory response — reported as granulomatous panniculitis (Zhu 2022^[6]), eosinophilic panniculitis (Ko 2020^[7]), and persistent nodules that in some cases needed intralesional steroid to resolve (Riswold 2018^[8]; Ito 2019^[9]). These nodules are usually a local tissue reaction to the injected product, not an allergy to the active drug, and they tend to settle once you rotate away from the area.

What helps an injection-site reaction

• Rotate your sites. Don't inject the same spot every week. Alternate among the abdomen (avoiding the area right around the navel), the front of the thighs, and the back of the upper arms. Systematic site rotation is the single best-evidenced way to reduce local reactions and lumps, carried over from injection-technique guidance for other subcutaneous medicines (Frid 2016^[16]).
• Check your technique. Let an alcohol swab dry fully before injecting, use a fresh needle each time, inject into subcutaneous fat (not muscle), and don't rub hard afterward. Storing the pen as directed and letting a refrigerated dose come toward room temperature can reduce sting.
• Soothe it. A cool compress and an over-the-counter antihistamine or low-strength hydrocortisone can ease itching and redness while it settles. Avoid scratching, which can prolong it or break the skin.
• Give nodules time. Firm bumps often take longer to disappear than redness; keep injecting elsewhere and they usually shrink over weeks. Mention any nodule that is growing, painful, warm, or draining to your prescriber.

Generalized rash and itching — less common

Some people develop itching or a rash away from the injection site — itchy patches, hives (raised, pale, intensely itchy welts that come and go), or diffuse itching without an obvious local cause. This is less common than the local reaction and has been described in the broader literature on GLP-1 cutaneous effects, alongside reports of other skin phenomena such as cutaneous allodynia — a heightened, sometimes uncomfortable skin sensitivity — in a tirzepatide case series (Chakrabarti 2026^[10]). A generalized rash is worth reporting to your prescriber because it sits in the middle of the spectrum: usually benign and antihistamine-responsive, but occasionally the first sign of a true drug hypersensitivity, so it deserves a closer look rather than being ignored.

Hives (urticaria) specifically are an itchy, raised, migrating rash driven largely by histamine release. Most acute hives are self-limited and respond to second-generation antihistamines, the first-line treatment in urticaria guidelines (Zuberbier 2022^[11]). If hives persist for weeks or recur, that is a separate clinical picture — our dedicated piece on chronic hives on a GLP-1 covers the workup and treatment, including when omalizumab (Xolair) enters the conversation. The key triage question with any hives is speed and company: hives that are spreading rapidly or come with any swelling of the face or throat or any breathing change are an emergency, not a nuisance.

Rare but serious — hypersensitivity reactions you must not miss

Serious allergic and hypersensitivity reactions to GLP-1 medications are rare, but because they are dangerous they are the reason to know the red flags cold. There are three patterns to recognize.

Anaphylaxis and angioedema (minutes to hours)

Anaphylaxis is a rapid, multi-system allergic reaction — typically within minutes to a couple of hours of a dose — that can include widespread hives, swelling, breathing difficulty, throat tightness, vomiting, a drop in blood pressure, dizziness, or collapse. Angioedema is deeper swelling, classically of the lips, tongue, face, or throat, that can compromise the airway. Both are medical emergencies: the World Allergy Organization guidance is unambiguous that suspected anaphylaxis is treated with intramuscular epinephrine without delay and emergency evaluation (Cardona 2020^[12]), and isolated angioedema of the airway likewise needs urgent care (acquired angioedema review, 2026^[13]). If this happens, the drug is stopped and not restarted except under specialist allergy guidance. The medication labels for GLP-1 receptor agonists list serious hypersensitivity reactions, including anaphylaxis and angioedema, as a known though uncommon risk and a reason to discontinue.

DRESS and severe delayed drug rashes (days to weeks)

A different and slower danger is a severe delayed drug reaction. The one to know by name is DRESS — Drug Reaction with Eosinophilia and Systemic Symptoms — which typically appears two to eight weeks after starting a culprit drug and combines a widespread rash with fever, facial swelling, swollen lymph nodes, and internal-organ involvement (often the liver), with a high eosinophil count on bloodwork (Cacoub 2011^[14]). It is rare, but it is an emergency: it requires stopping the drug immediately and hospital-level care, because organ involvement can be life-threatening. A rash that arrives with fever and facial swelling weeks into treatment is therefore a fundamentally different signal from a small itchy welt at the injection site on dose-day, and must be treated as serious.

Compounded GLP-1 products and excipient reactions

One nuance specific to compounded semaglutide and tirzepatide: a skin reaction may be a response to what else is in the vial, not just the active peptide. Compounded products can use different salt forms, preservatives, buffers, and excipients than the FDA-approved branded pens, and a preservative or excipient is a plausible trigger for a local or generalized skin reaction. Pharmacovigilance analysis of compounded GLP-1 receptor agonists using the FDA adverse-event reporting system has flagged that the safety profile of compounded products is less well characterized and warrants caution (McCall 2026^[15]). Practically: if you react on a compounded product, tell your prescriber and pharmacy, ask exactly what the formulation contains, and recognize that switching formulation or manufacturer can change the excipient exposure. None of this means a reaction is automatically the compounder's fault — but it is a variable worth naming when you and your clinician work out the cause.

How long does an Ozempic rash last?

• Injection-site reactions: usually a few days. Redness and itch typically peak within a day of the dose and fade over several days. Firm nodules can linger for weeks before resolving and occasionally need a clinician's help (e.g., intralesional steroid) (Riswold 2018^[8]).
• Acute hives / generalized rash: often days, sometimes resolving between doses; antihistamines speed relief. Hives lasting six weeks or more are considered chronic and need a different workup (Zuberbier 2022^[11]).
• Serious hypersensitivity: this isn't about waiting it out. Anaphylaxis and angioedema evolve over minutes to hours and need emergency treatment; DRESS evolves over days to weeks and needs hospital care — in both, the drug is stopped, not timed.

About "Ozempic rash pictures"

“Ozempic rash pictures” is one of the most common searches on this topic, and it is worth being honest about its limits. Photos can help you recognize a typical mild injection-site reaction — a coin-sized patch of redness or a small welt at the jab site — but they are a poor and sometimes dangerous tool for diagnosing the serious reactions, which are defined by what they do (spread fast, swell the airway, add fever and organ symptoms) more than by a single still image. A photo cannot tell you whether your lip swelling is progressing or whether your fever-plus-rash is DRESS. Use images to calm reasonable worry about a small local bump; use the red-flag checklist, not a photo gallery, to decide whether something is an emergency. When in doubt, send a photo to your own clinician and describe the timeline and symptoms.

Bottom line

• “Ozempic rash” covers three different things — a common mild injection-site reaction, a less common generalized rash or itching, and a rare but serious hypersensitivity reaction. Keeping them separate is the whole game.
• Injection-site reactions (redness, itch, a small welt or nodule at the jab site) are usually mild and self-limited; rotate sites, refine technique, soothe, and they typically settle (Frid 2016^[16]; Marso 2016^[3]).
• Generalized rash or hives is less common, often antihistamine-responsive, and worth reporting because it occasionally signals true hypersensitivity (Zuberbier 2022^[11]).
• Serious hypersensitivity — fast-spreading hives, airway swelling/angioedema, anaphylaxis (Cardona 2020^[12]), or delayed rash-plus-fever DRESS (Cacoub 2011^[14]) — is rare but an emergency: stop the drug and seek care.
• These reactions apply to both semaglutide and tirzepatide; with compounded products, an excipient or preservative can also be the trigger (McCall 2026^[15]).
• Use “rash pictures” to reassure yourself about a small local bump — but use the red-flag checklist, not a photo, to decide if something is serious.

Related research

• Chronic hives on a GLP-1 — when itchy welts last six weeks or more, the workup, and where omalizumab fits.
• GLP-1 side-effect questions answered — a plain-language tour of the common and less-common effects of semaglutide and tirzepatide.

Important disclaimer. This article is educational and does not constitute medical advice. Skin reactions vary widely between individuals, and the same symptom can be trivial in one person and serious in another. If you have any red-flag symptom — airway or facial swelling, breathing difficulty, fast-spreading hives, fainting, or a rash with fever — seek emergency care immediately and do not take another dose until evaluated. For any persistent or worsening rash, contact your prescriber. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-19.